Search

Your search keyword '"Doxazosin Mesylate"' showing total 88 results

Search Constraints

Start Over You searched for: Descriptor "Doxazosin Mesylate" Remove constraint Descriptor: "Doxazosin Mesylate"
88 results on '"Doxazosin Mesylate"'

Search Results

2. Mechanical, optical, and physicochemical properties of HPMC-based doxazosin mesylate orodispersible films

Catalog

Books, media, physical & digital resources

3. Determination of antihypertensive drugs irbesartan and doxazosin mesylate in healthcare products and urine samples using surface-enhanced Raman scattering.

4. 甲磺酸多沙唑嗪在女性膀胱过度活动症的临床应用.

5. Aggregation of Gold Nanoparticles for Spectrophotometric Determination of Bisoprolol Hemifumarate, Buspirone HCl and Doxazosin Mesylate

7. Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate: in vitro, and in vivo evaluation.

8. A Rapid and Sensitive Reversed Phase Liquid Chromatography-Tandem Mass Spectrometry Method For Quantification Of Doxazosin Mesylate In Human Plasma Using Doxazosin Mesylate D8 As Internal Standard.

9. Aggregation of Gold Nanoparticles for Spectrophotometric Determination of Bisoprolol Hemifumarate, Buspirone HCl and Doxazosin Mesylate.

10. New Approach for Administration of Doxazosin Mesylate: Comparative Study between Liquid and Solid Self-nanoemulsifying Drug Delivery Systems

11. Development and Validation of a Reversed-Phase HPLC Method for Simultaneous Determination of Doxazosin Mesylate and Finasteride.

12. Improved Hypertension by Investigating Circadian Rhythm of Blood Pressure

13. Linear pharmacokinetics of doxazosin in healthy subjects

14. Extractive spectrophotometric determination of some α-adrenergic-antagonists in pure forms and in pharmaceutical formulations

15. A Rapid and Sensitive Reversed Phase Liquid Chromatography-Tandem Mass Spectrometry Method For Quantification Of Doxazosin Mesylate In Human Plasma Using Doxazosin Mesylate D8 As Internal Standard

16. Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate: in vitro, and in vivo evaluation

17. Doxazosin Free-Base Structure Determination and Its Equilibrium Solubility Compared to Polymorphic Doxazosin Mesylate Forms A and H

18. Micellar enhanced spectrofluorimetric approach for nanogram detection of certain α1‐blocker drugs: Application in pharmaceutical preparations and human plasma

19. pH-independent sustained release matrix tablet containing doxazosin mesylate: Effect of citric acid.

20. Matrix tablets based on carrageenans with dual controlled release of doxazosin mesylate

21. Doxazosin mesylate affects localization of endothelin-1 in prostatic tissues.

22. LC–MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers

23. Development and validation of a reversed-phase HPLC method for simultaneous determination of doxazosin mesylate and finasteride

24. A COMPLETE NMR STUDY OF DOXAZOSIN CHARACTERIZATION

25. Enantiomeric resolution of doxazosin mesylate and its process-related substances on polysaccharide chiral stationary phases

26. Syntheses of molecularly imprinted polymers and their molecular recognition study for doxazosin mesylate

27. Polymorphism of doxazosin mesylate.

28. Protonation site and hydrogen bnoding in anhydrous and hydrated crystalline forms of doxazosin mesylate from powder data.

29. Stability-indicating methods for the determination of doxazosin mezylate and celecoxib

30. Effects of doxazosin mesylate versus nifedipine on blood pressure variability in hypertensive patients: a randomized crossover study (SIMILAR)

31. Fast disintegrating tablet of Doxazosin Mesylate nanosuspension: Preparation and characterization

32. Spectrophotometric determination of buspirone HCl and doxazosin mesylate using citrate-capped silver nanoparticles

34. Preparation and characterization of controlled-release doxazosin mesylate pellets using a simple drug layering-aquacoating technique

36. Extractive spectrophotometric determination of some α-adrenergic-antagonists in pure forms and in pharmaceutical formulations

37. Homologous recombination induced by doxazosin mesylate and saw palmetto in theDrosophilawing-spot test

38. Determination of Alkyl Methanesulfonates in Doxazosin Mesylate by Gas Chromatography-mass Spectrometer

40. Selective α1-adrenoceptor antagonist (controlled release tablets) in preoperative management of pheochromocytoma

41. A LC-MS-MS Method for Determination of Low Doxazosin Concentrations in Plasma after Oral Administration to Dogs

42. Doxazosin mesylate affects localization of endothelin-1 in prostatic tissues

43. Spectroscopic Studies and Applications of the Reactions of Some Anti-Diabetic and Anti-Hypertensive Drugs with Rose Bengal

44. Pharmacokinetics of Doxazosin Gastrointestinal Therapeutic System after Multiple Administration in Korean Healthy Volunteers

45. Synthesis, vasorelaxant activity and 2D-QSAR study of some novel pyridazine derivatives

46. Highly sensitive spectrofluorimetric method for determination of doxazosin through derivatization with fluorescamine; Application to content uniformity testing

47. Development and validation of a reversed-phase HPLC method for monitoring of synthetic reactions during the manufacture of a key intermediate of an anti-hypertensive drug

48. Syntheses of molecularly imprinted polymers and their molecular recognition study for doxazosin mesylate

49. Prostate apoptosis after doxazosin treatment in the spontaneous hypertensive rat model

50. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C9*1/*3 genotype